Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs... Read more

Stock Quote

PTGX (Common Stock)
$8.22 - 0.37 (4.31%)
Exchange :NASDAQ
Volume :32,285
Today's Open$8.40
Previous Close$8.59
Data as of May 26, 2017 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $8.22 with a 52 week high of $26.36 and a 52 week low of $8.00.

Recent Press Releases

May 25, 2017

Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 read more

May 24, 2017

Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity read more

May 10, 2017

Protagonist Therapeutics Reports First Quarter 2017 Financial Results read more

Upcoming Events

There are currently no events scheduled.

Presentation

Investor Presentation

Data provided by Nasdaq. Minimum 15 minutes delayed.